Regimen Reference Order – HEME – ruxolitinib (myelofibrosis)

Planned Course: **Twice daily until disease progression or unacceptable toxicity (1 cycle = 28 days)**

Indication for Use: **Myelofibrosis**

Proceed with treatment if:

- ***ANC equal to or greater than 0.5 x 10^9/L AND Platelets equal to or greater than 50 x 10^9/L***
- ***Hemoglobin equal to or greater than 80 g/L***
  - **Contact Hematologist if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – HEME ruxolitinib (myelofibrosis)

Drug	Initial Dose	Criteria for initial dose
ruxolitinib	20 mg orally twice daily	IF platelet value is greater than 200 X 10^9/L
	15 mg orally twice daily	IF platelet value is between 100 to 200 X 10^9/L
	5 mg orally twice daily	IF platelet value is between 50 to 100 X 10^9/L
ruxolitinib (Jakavi®) available dosage strengths: 5 mg, 10 mg, 15 mg, 20 mg tablets **Classification: Cytotoxic, Hazardous**		

REQUIRED MONITORING

- CBC, biochemistry, serum creatinine, liver function tests at baseline, then every 2 – 4 weeks until dose is stabilized then as clinically indicated thereafter as per physician order
- Before starting treatment, patients should be evaluated for active and latent tuberculosis, hepatitis B and C, HIV serology
- ECG at baseline and then as required
- Blood pressure and pulse rate should be evaluated at each physician appointment

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
valacyclovir	500 mg	Orally once daily **(self-administered at home)** *valacyclovir will only be prescribed for patients at risk of herpes zoster

INSTRUCTIONS FOR PATIENT

- ruxolitinib may be taken with or without food
- Patients should:
    - be instructed that their dose may be adjusted during their course of therapy
    - be advised not to stop ruxolitinib abruptly as rebound symptoms can occur
    - be aware of the risk of low blood counts and to report any signs or symptoms of infection
    - be aware that ruxolitinib can increase the risk of non-melanoma skin cancers and to report any new or changing skin lesions
    - be aware that ruxolitinib can increase cholesterol levels
- Patients should not receive the shingles vaccine while on ruxolitinib
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after ruxolitinib

ADDITIONAL INFORMATION

- N/A